Medically reviewed by Dr. Pedro Martinez-Clark, MD and Dr. William O'Neill, MD. Last reviewed: July 2026.
Mexico offers the fastest median trial start-up time in Latin America (2.8 months), US-adjacent time zones, and a landmark Trusted Regulatory Practices framework that recognizes FDA and EMA approvals. With 130M+ patients and COFEPRIS modernization, Mexico is an increasingly strategic choice for first-in-human studies.
Mexico has undergone a regulatory transformation that positions it as one of the most attractive markets for clinical trials in the Americas. COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) implemented a landmark Trusted Regulatory Practices (Reliance) framework that allows recognition of Phase III approvals from the FDA, EMA, MHRA, and Health Canada — materially reducing time to authorization for experienced sponsors.
Mexico's median trial start-up time of approximately 2.8 months is the fastest in Latin America, according to NIH ClinRegs data. Ethics committee review must be completed before COFEPRIS authorization, and all submissions must be made in Spanish. bioaccess® handles the entire regulatory process, from protocol translation to COFEPRIS correspondence, with a Mexico City-based regulatory affairs team.
For MedTech startups, Mexico offers a unique combination of advantages: same time zone as the US (Central/Mountain), direct flights from every major US city, a 130M+ patient population, and per-patient costs of $18K–$30K. Mexico City, Guadalajara, and Monterrey host world-class medical centers with investigators who maintain active relationships with US academic institutions.
COFEPRIS governs all clinical investigations in Mexico under the General Health Law (Ley General de Salud) and its implementing regulations. For medical device clinical trials, sponsors submit a clinical investigation application including the protocol, investigator brochure, informed consent, ethics committee approval, and proof of insurance. COFEPRIS reviews typically take 4–8 weeks after ethics committee clearance. bioaccess® manages the entire process in Spanish.
Mexico's Reliance framework, documented by Perez-Llorca, allows COFEPRIS to recognize regulatory decisions from trusted authorities (FDA, EMA, MHRA, Health Canada). While primarily applicable to marketing authorizations, this framework signals Mexico's alignment with international regulatory standards and creates a favorable environment for sponsors with existing FDA interactions.
Ethics committee review in Mexico must be completed before COFEPRIS authorization is submitted. Institutional ethics committees follow NOM-012-SSA3-2012 guidelines for clinical research. Review timelines average 4–6 weeks. bioaccess® works with pre-established ethics committees at our partner hospitals in Mexico City, Guadalajara, and Monterrey to ensure efficient review.
Mexico shares time zones with the US Central and Mountain regions, enabling real-time communication between sponsors and clinical sites. Direct flights from Miami (3 hours), Houston (2.5 hours), Los Angeles (3.5 hours), and New York (5 hours) make site visits convenient. bioaccess® coordinates sponsor visits and can arrange OR observation for device studies at partner hospitals.
| Metric | Mexico 🇲🇽 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Regulatory start-up (median) | ~2.8 months (COFEPRIS + EC) | 6–12 months (IDE + IRB) | 3–6 months (per-country CA + EC) |
| Cost per patient | $18K–$30K | $40K–$75K | $35K–$60K |
| Reliance on FDA/EMA decisions | Yes — Trusted Regulatory Practices | Native | Limited |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Time zone vs. US | Same (Central/Mountain) | Same | +6 to +9 hours |
| Patient population | 130M+ | 330M+ | ~450M (fragmented) |
| Direct flights from US | 2.5–5 hours | Domestic | 9–11 hours |
Ranges reflect bioaccess® first-in-human medical device studies. Actual costs and timelines vary by device complexity, therapeutic area, and monitoring requirements.
COFEPRIS review typically takes 4–8 weeks after ethics committee clearance. Combined with the ethics committee review period (4–6 weeks), total regulatory start-up averages 2.8 months — the fastest in Latin America. bioaccess® manages the entire process in Spanish.
COFEPRIS implemented a Reliance framework that allows recognition of regulatory decisions from the FDA, EMA, MHRA, and Health Canada. This reduces duplication and signals Mexico's alignment with international standards, creating a favorable environment for sponsors who have existing FDA interactions or prior regulatory history.
Per-patient costs in Mexico range from $18,000–$30,000 depending on device complexity and therapeutic area. A 10-patient FIH study typically costs $280K–$400K — compared to $750K–$1.5M in the United States. Mexico's costs are competitive with Colombia while offering proximity and timezone advantages.
Yes. All COFEPRIS submissions must be in Spanish, including the protocol, investigator brochure, and informed consent documents. bioaccess® handles all translation and localization, ensuring regulatory terminology is accurate and culturally appropriate for Mexican ethics committees and investigators.
Mexico City offers the largest concentration of tertiary care hospitals and sub-specialty investigators. Guadalajara has strong cardiology and orthopedic programs. Monterrey provides advanced surgical and oncological capabilities. bioaccess® has 10+ pre-qualified sites across these cities with investigators who maintain active relationships with US academic institutions.
Yes. Mexico's proximity is a major advantage. Direct flights from Miami (3 hours), Houston (2.5 hours), Los Angeles (3.5 hours), and New York (5 hours) make site visits convenient. Mexico shares time zones with the US Central and Mountain regions, enabling real-time communication between sponsors and clinical teams.
All countries we serve · Contact bioaccess® · First-in-Human CRO